Gambichler Thilo, Bischoff Stefan, Bechara Falk G, Altmeyer Peter, Kreuter Alexander
Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, 44791, Bochum, Germany.
J Dermatol Sci. 2008 Feb;49(2):125-32. doi: 10.1016/j.jdermsci.2007.07.011. Epub 2007 Sep 10.
Abnormal cell proliferation, which results from deregulation of the cell cycle, is fundamental in tumorigenesis.
To investigate the expression of proliferation markers and cell cycle regulators in a range of T cell lymphoproliferative skin diseases.
We studied skin specimens of 51 patients with parapsoriasis (PP), mycosis fungiodes (MF), or lymphomatoid papulosis (LyP). Immunohistochemistry was performed for Ki-67, proliferating cell nuclear antigen (PCNA), minichromosome maintenance protein 7 (MCM7), and p21.
MF with stage IIB-IV and LyP showed a significantly greater number of Ki-67-positive cells than PP (P=0.02 and 0.001) and MF I-IIA (P=0.019 and 0.003), respectively. MCM7 staining revealed significantly higher labeling indices for MF IIB-IV and LyP when compared to PP (P=0.002 and 0.04) and MF I-IIA (P=0.0005 and 0.01), respectively. Compared to PP and MF I-IIA, MF IIB-IV was associated with significantly higher labeling indices for PCNA (P=0.006 and 0.0004). p21 staining was significantly increased in MF IIB-IV and LyP when compared to PP (P=0.006 and 0.003) and MF I-IIA (P=0.003). However, p21 staining was all in all very weak.
Ki-67 and PCNA seem to be useful immunohistological parameters for the correlation with the clinical stage of MF. In the differentiation and prognostication of T cell lymphoproliferative skin disorders, MCM7 may serve as a novel biomarker which is, in contrast to Ki-67 and PCNA, stable throughout the cell cycle.
细胞周期失调导致的异常细胞增殖是肿瘤发生的根本原因。
研究多种T细胞淋巴增殖性皮肤病中增殖标志物和细胞周期调节因子的表达情况。
我们研究了51例副银屑病(PP)、蕈样肉芽肿(MF)或淋巴瘤样丘疹病(LyP)患者的皮肤标本。对Ki-67、增殖细胞核抗原(PCNA)、微小染色体维持蛋白7(MCM7)和p21进行免疫组织化学检测。
IIB-IV期MF和LyP中Ki-67阳性细胞数量分别显著多于PP(P = 0.02和0.001)以及MF I-IIA期(P = 0.019和0.003)。MCM7染色显示,与PP(P = 0.002和0.04)和MF I-IIA期(P = 0.0005和0.01)相比,MF IIB-IV期和LyP的标记指数显著更高。与PP和MF I-IIA相比,MF IIB-IV期PCNA的标记指数显著更高(P = 0.006和0.0004)。与PP(P = 0.006和0.003)和MF I-IIA期(P = 0.003)相比,MF IIB-IV期和LyP中p21染色显著增加。然而,总体而言p21染色非常弱。
Ki-67和PCNA似乎是与MF临床分期相关的有用免疫组织学参数。在T细胞淋巴增殖性皮肤疾病的鉴别和预后评估中,MCM7可能作为一种新型生物标志物,与Ki-67和PCNA不同,它在整个细胞周期中都很稳定。